OMass Therapeutics’ Post

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #5. We are responsible: We take personal and collective responsibility for delivering our shared goals. We hold ourselves and each other accountable – to our patients, colleagues, investors, as well as our work and mission. We apply the necessary rigor to ensure high quality. We are self-motivated and rely on each other to operate and perform at the highest levels. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #2. We have resilience of spirit: When we hit a stumbling block, our ingenuity helps us remain agile and allows us to find new ways towards our goals. In the spirit of continuous learning and improvement, we accept that not everything will work first time, and we learn from any failures. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #3. We are ambitious: We are driven by our shared mission to discover, develop and deliver impactful medicines to patients using cutting edge science. We are motivated to push boundaries and think big as we tackle challenges we confront as a company. We take a proactive approach towards research, and we are intentional in setting our short-term and long-term goals. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

Our Better Biotech Growth webinar series kicks off this September! Join Simone Seiter and Kevin Baruzzi as they reveal how to transform scientific innovations into market successes. Learn to create a winning product strategy and integrate key insights from various stakeholders to achieve commercial excellence. Don't miss this opportunity! Register now: skp.link/rw7l #BetterBiotechGrowth #Biotech #CommercialExcellence #SimonKucher #BiotechGrowth

Our Better Biotech Growth webinar series kicks off this September! Join Simone Seiter and Kevin Baruzzi as they reveal how to transform scientific innovations into market successes. Learn to create a winning product strategy and integrate key insights from various stakeholders to achieve commercial excellence. Don't miss this opportunity! Register now: skp.link/rw7l #BetterBiotechGrowth #Biotech #CommercialExcellence #SimonKucher #BiotechGrowth

Exciting insights from our recent roundtables, hosted in partnership with @AusBiotech. We were joined by more than 90 Biotech CEOs to discuss funding challenges, navigating regulatory changes, and talent acquisition. Read more about our discussions and how we can support your journey: https://lnkd.in/gwNc4P48

Our Better Biotech Growth webinar series kicks off this September! Join Simone Seiter and Kevin Baruzzi as they reveal how to transform scientific innovations into market successes. Learn to create a winning product strategy and integrate key insights from various stakeholders to achieve commercial excellence. Don't miss this opportunity! Register now: skp.link/rw7l #BetterBiotechGrowth #Biotech #CommercialExcellence #SimonKucher #BiotechGrowth

Our Better Biotech Growth webinar series kicks off this September! Join Simone Seiter and Kevin Baruzzi as they reveal how to transform scientific innovations into market successes. Learn to create a winning product strategy and integrate key insights from various stakeholders to achieve commercial excellence. Don't miss this opportunity! Register now: skp.link/rw7l #BetterBiotechGrowth #Biotech #CommercialExcellence #SimonKucher #BiotechGrowth

Navigating the funding landscape can be tricky for biotech companies at all stages, from initial research and clinical trials to scaling up capabilities. Our recent roundtable discussions with over 90 Biotech CEOs, held in partnership with AusBiotech, shed light on the challenges and opportunities shaping the industry. Discover how to navigate the complexities of funding and innovation in the biotech sector in our latest article: https://okt.to/ugJm1o #Biotech #LifeSciences

📈 Everyone from #polishbiotech ecosystem is super fascinated with recent financial successes of #biotech companies such as Celon Pharma S.A. , NanoGroup S.A. or Pure Biologics (detailed analysis in articles cited in comm. 👇) I am also glad about above mentioned results as they are showcasing that investors don’t need to be afraid of biotech companies and it builds their TRUST - the most valuable asset. 💰 ❗️I just would like to highlight that these results didn’t come out of nowhere. They are coming out of huge resilience of the leaders such as Maciej Wieczorek or Pawel Przewiezlikowski that show that right planning will get you to success (depending on how one defines one). This resilience and trust are what keep me also pushing on forward #polishbiotech and showcasing it on the global scene 🌎 - with small steps & with big help of people thinking alike 💪 I am aware that Polish biotech companies still have long way to go to be compared to international players in the field, but I strongly believe that #cooperation will get us there and this is what Central European BioForum stands for. 🎯I hope to see everyone interested in #biotech #business on at #CEBioForum2025📍2-3 APRIL / Warsaw Photo credit: Aleksander Kłósek at #BIO2024